Is Cidara Therapeutics Inc (CDTX) Stock About to Get Hot Wednesday?

Cidara Therapeutics Inc (CDTX) stock has risen 8.11% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Cidara Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CDTX!

See Full CDTX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With CDTX Stock Today?

Cidara Therapeutics Inc (CDTX) stock is trading at $1.60 as of 11:19 AM on Wednesday, Dec 8, a decline of -$0.03, or -2.15% from the previous closing price of $1.63. The stock has traded between $1.56 and $1.61 so far today. Volume today is less active than usual. So far 86,210 shares have traded compared to average volume of 685,377 shares. To see InvestorsObserver's Sentiment Score for Cidara Therapeutics Inc click here.

More About Cidara Therapeutics Inc

Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Click Here to get the full Stock Report for Cidara Therapeutics Inc stock.